Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Effect Of Diabetes Coaching on Diabetes Self-Management, Glycoslated Hemoglobin and Diabetes Distress Level in Indıviduals With Type 2 Diabetes: A Randomized Controlled Study
This research is a randomized controlled, experimental study planned to evaluate the effect of diabetes coaching on diabetes self-management, glycosylated hemoglobin and diabetes distress levels in individuals with type 2 diabetes. The research is planned to start on 01.01.2024. Participants will be divided into experimental and control groups using the block randomization method. Participants in the experimental group will first receive 8 sessions of diabetes coaching every 10 days after the chemistry interview. No intervention will be made to the control group. The preliminary implementation of the research will be carried out with 4 individuals with diabetes who voluntarily accept participation and meet the inclusion criteria. Data will be collected by face-to-face interview method. Data will be analyzed with IBM SPSS V23 program.
| Status | Not yet recruiting |
| Enrollment | 64 |
| Est. completion date | December 31, 2027 |
| Est. primary completion date | December 31, 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 65 Years |
| Eligibility | Inclusion Criteria: - Volunteering to participate in the study, - Having been diagnosed with Type 2 diabetes for at least 1 year, - Being between the ages of 18-65, - No communication problems, - Being literate, - Being able to use a phone (home or mobile phone), - Lack of diagnosis of psychiatric disease, - Not receiving hospital treatment due to acute problems, - Not to be involved in another study involving a similar intervention during the research period Exclusion Criteria: - Being diagnosed with type 1 diabetes, - Type 2 diabetes diagnosis period is less than one year, - Being under 18 years of age, over 65 years of age, - Being pregnant, - Having a diagnosis of psychiatric disease, - Not agreeing to participate in the research |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Abant Izzet Baysal University |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Type 2 Diabetes Self-Management Scale | This scale was developed by Koç and Özkan to evaluate self-management in type 2 diabetics and is a 5-point Likert type ("Always=5", "Often=4", "Sometimes=3") , "Rarely=2", "Never=1"). The sub-dimensions of the scale, which consists of a total of 19 questions; "Healthy Lifestyle Behaviors" (11 items), "Use of Health Services" (4 items) and "Blood Sugar Management" (4 items). The highest score that can be obtained from the scale is 95 and the lowest score is 19. As the score obtained from the scale increases, diabetes self-management increases. The Cronbach alpha value of the scale was calculated as 0.856 (37) | 3 months | |
| Secondary | Diabetes Distress Scale | The Diabetes Distress Scale is a 17-item, 6-point Likert type scale developed by Polonsky et al. in 2005 to evaluate diabetes-specific distress. The scale consists of four subscales: emotional burden, doctor-related distress, treatment-related distress, and interpersonal distress. Each question in the scale is scored between 1 point and 6 points, and the scale evaluates the distress experienced by the individual in the last month (40). The validity and reliability study of the scale was conducted by Çakilli et al. in 2015, and the a value was found to be 0.88 for the entire scale and 0.90 for each of the subscales. The average total score of the scale is calculated by dividing the total score of the answers given to the scale by 17. A score of 3 points or higher suggests the presence of distress. Score calculation for the sub-dimensions is obtained by dividing the total score of the answers given to the questions by the number of questions in that section (40,41) | 3 months | |
| Secondary | HbA1c Monitoring Form | This is the form created to monitor the HbA1c values of individuals with diabetes before and after the application and to follow the changes (Annex 3). HbA1c is a routine test evaluated every three months in the follow-up of individuals with diabetes. Individuals will be included in the study if they have HbA1c tests within the last 10 days when they come to the Family Health Care, otherwise they will be included in the study when they have the test done on a date suitable for routine control. | 3 months | |
| Secondary | Introductory Features Form | The form was prepared by the researcher by conducting a literature review and consists of a total of 23 questions (32,34,37-39). In this form, in the first section; Questions about age, gender, education level, marital status, perceived income level, who the individual lives with, smoking and alcohol use, and the presence of chronic diseases. In the second part, there are questions about diabetes; duration of diabetes diagnosis, type of diabetes treatment, status of receiving diabetes education, HbA1c value measured in the last 10 days, presence and types of complications due to diabetes, regular use of diabetes medications, how diabetes care is carried out, status of receiving diabetes education (from whom, training subject , when it was taken, etc.) are included | 3 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
| Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
| Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
| Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
| Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
| Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
| Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
| Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
| Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
| Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
| Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
| Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
| Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
| Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
| Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
| Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
| Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |